

# Synthesis and Physico-Chemical Properties in Aqueous Medium of All Possible Isomeric Bromo Analogues of Benzo-1H-Triazole, Potential Inhibitors of Protein Kinases


Romualda Wąsik,<sup>†</sup> Patrycja Wińska,<sup>†,§</sup> Jarosław Poznański,<sup>\*,†</sup> and David Shugar<sup>\*,†,‡</sup>

<sup>†</sup>Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawińskiego 5a, 02-106 Warszawa, Poland

<sup>‡</sup>Division of Biophysics, Institute of Experimental Physics, University of Warsaw, Żwirki i Wigury 93, 02-089 Warszawa, Poland

## S Supporting Information

**ABSTRACT:** In ongoing studies on the role of the individual bromine atoms of 4,5,6,7-tetrabromobenzo-1H-triazole (TBBt) in its relatively selective inhibition of protein kinase CK2 $\alpha$ , we have prepared all the possible two mono-, four di-, and two tri-bromobenzo-1H-triazoles and determined their physicochemical properties in aqueous medium. They exhibited a general trend of a decrease in solubility with an increase in the number of bromines on the benzene ring, significantly modulated by the pattern of substitution. For a given number of attached bromines, this was directly related to the electronic effects resulting from different sites of substitution, leading to marked variations of pK<sub>a</sub> values for dissociation of the triazole proton. Experimental data (pK<sub>a</sub>, solubility) and *ab initio* calculations demonstrated that hydration of halogenated benzotriazoles is driven by a subtle balance of hydrophobic and polar interactions. The combination of QM-derived free energies for solvation and proton dissociations was found to be a reasonably good predictor of inhibitory activity of halogenated benzotriazoles vs CK2 $\alpha$ . Since the pattern of halogenation of the benzene ring of benzotriazole has also been shown to be one of the determinants of inhibitory potency vs some viruses and viral enzymes, the present comprehensive description of their physicochemical properties should prove helpful in efforts to elucidate reaction mechanisms, including possible halogen bonding, and the search for more selective and potent inhibitors.



## 1. INTRODUCTION

The steadily increasing number of protein structures accessible in the PDB (~75 000) includes over 50 000 with bound ligands, thus providing a unique source of information on modes of interaction between proteins and their ligands. The initial pattern of such interactions, e.g., electrostatic, van der Waals (vdW), and hydrogen bonding, continues to be extended, e.g., to a C–H group functioning as a hydrogen bond donor, and a  $\pi$ -electron system as a hydrogen bond acceptor.

The past decade has witnessed identification of many specific interactions between halogen atoms (Cl, Br, I) of halogenated ligands and the electron pairs of oxygen/nitrogen/sulfur. These interactions, analogous to that of a hydrogen bond, and now commonly referred to as halogen bonds, have been identified in many crystal structures of supramolecular ensembles, as well as in complexes between biomolecules and halogenated ligands. In both cases, this is based in part on the observation that the distance between a halogen atom and its electron-donating partner is significantly lower than the sum of their vdW radii.

Bearing in mind that some natural, and an increasing number of synthetic, drug candidates are halogenated,<sup>1–3</sup> understanding the nature and thermodynamics of halogen bonding should contribute to rational drug design.<sup>4</sup> Halogenated compounds comprise a significant part of current screening libraries, and almost 20% of low-mass protein ligands listed in the PDB are

halogenated (694 fluorinated listed in 919 PDB records, 992/1323 chlorinated, 281/518 brominated, and 110/254 iodinated).<sup>5</sup> Current widespread interest in elucidating the role of halogenated ligands in biological systems has been extensively reviewed, among others, by Voth and Ho,<sup>6</sup> Parisini et al.,<sup>7</sup> and Metrangola et al.<sup>8,9</sup>

Despite the increasing number of crystal structures of complexes of proteins with halogenated ligands, only limited experimental data are available on intermolecular halogen bonding of molecules in solution.<sup>10–14</sup> Temperature-dependent changes of infrared spectra recorded for mixtures of trifluorohalomethanes and trimethylamine (TMA) dissolved in liquidized noble gases (xenon, krypton, argon) enabled Hauchecorne et al.<sup>15</sup> to estimate the enthalpy of formation of halogen bonded complexes as –6.8, –4.4, and –2.1 kcal/mol for TMA complexes with CF<sub>3</sub>I, CF<sub>3</sub>Br, and CF<sub>3</sub>Cl, respectively, while the enthalpy of formation of CF<sub>3</sub>H–TMA complexes in liquid argon and krypton was estimated as –3.5 kcal/mol,<sup>16</sup> hence between CF<sub>3</sub>Br and CF<sub>3</sub>Cl. Moreover, in real systems, especially in aqueous medium, the entropic contribution to the free energy may significantly decrease the stability of halogen-bonded complexes, strongly supported by computational

Received: February 16, 2012

Revised: May 22, 2012


Published: May 25, 2012

studies on potential halogen bonding interactions in solution, which showed that, at least for neutral systems, formation of halogen-bonding complexes is entropically disfavored.<sup>17</sup> Furthermore, a water molecule was found to be a very weak halogen-bond acceptor in both polar and nonpolar media,<sup>17</sup> suggesting that the thermodynamics of solvation of halogenated compounds in aqueous medium is dominated by a balance of hydrophobic and electrostatic interactions.

Halogen bonding interactions were found responsible for ligand recognition in numerous protein structures deposited in the PDB.<sup>18</sup> There are, however, only very limited data concerning halogen bonding with biomolecules in solution, and no consensus about the energetics involved.<sup>19–22</sup> As demonstrated for halogenated protein ligands, contributions of enthalpic (e.g., electrostatic) and entropic (e.g., hydrophobic) interactions were virtually the same.<sup>23–26</sup>

Our interest in the foregoing stems from the finding that the first reported low-molecular weight potent, and relatively selective, inhibitor of the ubiquitous protein kinase CK2 (and its catalytic subunits CK2 $\alpha$ ) is 4,5,6,7-tetrabromobenzo-1H-triazole (TBBt, Scheme 1),<sup>27</sup> a potential halogen bond donor.

Scheme 1



Subsequently, 4,5,6,7-tetrabromobenzoimidazole (TBBz) was found to be a comparably good inhibitor.<sup>28</sup> An even more potent one was recently reported, 4,5,6,7-tetrabromoindazole (compound K59).<sup>29</sup>

We have previously shown<sup>30</sup> that replacement of one of the bromines of TBBt, that at C(5), by a variety of other substituents, differing in size, electronegativity, and hydrophobicity, resulted in significant changes in ionic equilibrium, a protomeric preference for the neutral form, and inhibitory activity vs human CK2 $\alpha$ . The majority of these 5-substituted 4,6,7-tribromobenzotriazole derivatives displayed inhibitory activity comparable to that of TBBt, the most efficient among the 18 studied compounds. Overall, the hydrophobicity of the monoanionic form of the ligand appeared to be the principal factor governing its inhibitory activity.

Inspection of crystal structures of 4,5,6,7-tetrabromobenzo-triazole (record 1J91, TBBt, also known as TBB),<sup>27</sup> 4,5,6,7-tetrabromobenzoimidazole (2OXY, TBBz, compound K17),<sup>28</sup> and 3,4,5,6,7-pentabromoindazole (3KXG, compound K64)<sup>29</sup> (see Scheme 1) in complex with CK2 $\alpha$  reveals significant differences in their location in the CK2 $\alpha$  binding site, as well as in the topology of the intermolecular halogen bonds; see ref 29 for detailed analysis. Furthermore, the binding mode of TBBt to CDK2, a close homologue of CK2 $\alpha$ , resembles that of TBBz but not TBBt, in complex with CK2 $\alpha$ , including ligand orientation and two side-chain carbonyls involved in halogen bonding.<sup>31</sup> These differences clearly indicate that binding of a halogenated ligand, at least to CK2 $\alpha$ , is driven by a balance of electrostatic, hydrophobic, hydrogen-bonding, and halogen-bonding interactions, with the electrostatic component being predominant, supported also by analysis of the structure–activity

relations for a series of 5-substituted 4,6,7-tribromobenzotriazoles<sup>30</sup> (see above). The majority of these displayed IC<sub>50</sub> values comparable to that of TBBt but, generalizing, demonstrated that hydrophobic interactions, corrected for dissociation of the triazole proton in aqueous medium, predominate in stabilization of the protein–ligand complexes. The results also indicated that eventual contribution of halogen bonding to the final free energy of complex formation is at least one order of magnitude lower than that of hydrophobic interactions. It should however be noted that, for the analyzed compounds, there is a strong correlation between the number of halogen atoms and hydrophobic contribution to the free energy of ligand binding.<sup>30</sup>

To further clarify this, and to better define the role of the individual Br atoms of TBBt, as regards potency of inhibition of CK2 $\alpha$ , as well as to describe the thermodynamics of potential CK2 $\alpha$  inhibitors in aqueous medium, we have prepared the two mono-, the four di-, and the two tri-bromobenzotriazoles to provide, in addition to TBBt, the nine possible halogenation patterns of the benzene ring in benzotriazole, and to determine their physicochemical properties, including aqueous solubility and protonation equilibria, previously shown to be relevant to inhibitory activity against human CK2 $\alpha$ .<sup>30,32</sup>

Furthermore, bearing in mind that the pattern of halogenation of benzotriazoles (and benzimidazoles) has been shown to modulate their inhibitory activities vs some viruses and viral enzymes,<sup>33–35</sup> the present data should prove helpful in elucidation of the mechanisms involved.

## 2. EXPERIMENTAL SECTION

There are no reports on direct bromination of benzotriazole, with the exception of TBBt.<sup>36</sup> Preparation of bromo isomers of benzotriazole was carried out using different methods, including bromination of 2,1,3-benzothiadiazoles<sup>37</sup> or nitro analogues of aniline.<sup>38,39</sup> The 4,5,6-tribromobenzotriazole analogue was synthesized by nitration of the appropriate bromo analogue of benzene, whereas 4,5,7-tribromobenzotriazole (4,5,7-Br<sub>3</sub>Bt) was obtained by decarboxylation in quinoline of the parent 5-carboxy-4,5,7-tribromobenzotriazole.<sup>30</sup>

**General.** Starting materials: *o*-phenylenediamine (**1**), 2,4-dibromo-6-nitroaniline (**7**), and 1,2,3-tribromo-5-nitrobenzene (**9**) were from commercial sources (Aldrich), and were used without additional purification. The intermediate crude diamines, **6b** and **7b**, were used without further characterization.

Melting points (uncorr.) were determined in open capillary tubes, using a Büchi apparatus B504. UV absorption spectra were recorded on a Specord 200 instrument. Mass spectrometry was performed with a Micromass LTQ FT Ultra spectrometer. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded in CDCl<sub>3</sub> (benzothiadiazoles) or DMSO-*d*<sub>6</sub> (benzotriazoles) on an Inova 500 instrument. Spectra were analyzed with the aid of the MestRe-C (version 2.3a) program (see below).<sup>40</sup> Chemical shifts are in ppm relative to tetramethylsilane (Me<sub>4</sub>Si,  $\delta$  = 0).

All compounds were checked by thin-layer chromatography (TLC) on 0.2 mm Merck silica gel 60 F<sub>254</sub> plates. Preparative separations were carried out by column chromatography, using Merck silica gel (230–400 mesh), or on preparative glass plates (2 mm, Merck silica gel 60 F<sub>254</sub>), using the following solvent systems: (A) CHCl<sub>3</sub>:MeOH (9:1), (B) EtOAc:n-heptan:AcOH (2:2:0.2), (C) CHCl<sub>3</sub>.

**NMR Spectroscopy.** <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded at 298 K on a 500 MHz Varian spectrometer for

DMSO solutions of the ligands at concentrations, depending on solubility, in the range 100  $\mu$ M to 1 mM. All spectra were processed and analyzed with the aid of MestRec (version 2.3a).<sup>40</sup>  $^1\text{H}$  spectra were recorded in the range 0–10 ppm (24K data points) and processed using  $\pi/3$ -shifted squared sine-bell and zero-filling up to 32K data points prior to Fourier transformation.  $^{13}\text{C}$  spectra, recorded with broadband proton decoupling in the range 0–200 ppm and 32K data points, were processed using Lorentzian filtering, resulting in 15 Hz resonance broadening followed by a  $\pi/2$ -shifted squared sine-bell. The DMSO signal ( $^1\text{H}$  quintuplet at 2.50 ppm,  $^{13}\text{C}$  septuplet at 29.43 ppm) was used as the internal reference. Assignments for  $^1\text{H}$  resonances were done on the basis of line splitting patterns caused by homonuclear scalar coupling, while  $^{13}\text{C}$  resonance assignments were supported by GIAO-derived NMR shielding parameters (cf. Figure 1 in the Supporting Information for general correlation).

**UV-Monitored Titration.** Titration of the ligands in the pH range 2–12 was followed at 298 K on a Specord 200 UV–vis spectrometer equipped with a thermostatted cell holder. Changes in absorption were globally analyzed using the Henderson–Hasselbach formula:

$$\varepsilon(\lambda, \text{pH}) = \frac{\varepsilon_n(\lambda) \cdot 10^{\text{pH}} + \varepsilon_a(\lambda) \cdot 10^{\text{pK}_a}}{10^{\text{pH}} + 10^{\text{pK}_a}}$$

where  $\varepsilon(\lambda, \text{pH})$  is the spectrum recorded at a given pH and  $\varepsilon_n(\lambda)$  and  $\varepsilon_a(\lambda)$  are the reference spectra for the neutral and dissociated forms. The  $\text{pK}_a$  values were then estimated using the Marquardt–Levenberg algorithm<sup>41</sup> implemented in the Gnuplot program.<sup>42</sup>

**Solubility.** Aqueous solubilities of benzotriazole analogues were determined in buffered solution at pH 7.5. The suspensions were shaken at 25  $^\circ\text{C}$  in a shaker (Eppendorf Termomixer Comfort) for 96 h and then centrifuged. The concentration of clear supernatant was estimated from the spectra recorded in the range 220–300 nm.

**Synthetic Procedures.** **2,1,3-Benzothiadiazole (2).** To a suspension of 30 g (0.28 mol) of *o*-phenylenediamine (**1**) in dry toluene (300 mL) was added 90 mL (1.23 mol) of thionyl chloride. The mixture was heated under reflux for 3 h, followed by addition of 65 mL of thionyl chloride and 6 mL of dry pyridine in three portions of 2 mL each. Heating was continued for an additional 19 h. Distillation at 150  $^\circ\text{C}$  removed toluene and excess thionyl chloride. The fraction boiling at 200–220  $^\circ\text{C}$  was collected and, on cooling, the distillate of 2,1,3-benzothiadiazole solidified. The product was dissolved in ethanol, reprecipitated with water, collected, and washed with water to yield 31.2 g (82%) of **2**: mp 43.2–44.1  $^\circ\text{C}$  [lit. 44  $^\circ\text{C}$ <sup>37</sup>];  $R_f$  (C) 0.74;  $^1\text{H}$  NMR:  $\delta$  [ppm]: 8.01 (dd, 2H,  $J = 3.4, 6.8$  Hz, H-4, H-7); 7.6 (dd, 2H,  $J = 2.9$  Hz, 6.8 Hz, H-5, H-6).

**4-Bromo-2,1,3-benzothiadiazole (3a).** A 5 g portion (37 mmol) of 2,1,3-benzothiadiazole (**2**) was suspended in 10 mL of 47% HBr. The mixture was heated to reflux with stirring, and 1.9 mL (37 mmol) of  $\text{Br}_2$  was added portionwise for 2 h. Heating was continued for 1 h. The mixture was cooled and poured into ice water, and the resulting precipitate was collected by filtration. The crude product included small amounts of starting material and 4,7-dibromo-2,1,3-benzothiadiazole (**4a**), which were removed by steam-distillation. Crystallization from EtOH gave 4.34 g (55%) of pure product **3a**: mp 80.1–81.7  $^\circ\text{C}$  [lit. 80–81  $^\circ\text{C}$ <sup>37</sup>];  $R_f$  (C) 0.80;  $^1\text{H}$  NMR:  $\delta$  [ppm]: 7.98 (dd, 1H,  $J = 0.73$  Hz, 8.79 Hz, H-5); 7.85

(dd, 1H,  $J = 0.73$  Hz, 7.08 Hz, H-7); 7.48 (dd 1H  $J = 8.79$  Hz, 7.08 Hz, H-6).

**4-Bromobenzotriazole (3c, 4-BrBt).** A 150 mg portion (0.7 mmol) of 4-bromo-2,1,3-benzothiadiazole (**3a**) was ground in a mortar with 660 mg (3.48 mmol) of  $\text{SnCl}_2$  and added gradually to 10 mL of conc. HCl. The mixture was stirred for 2 h at room temperature, and the resulting white solid was filtered off and suspended in 25% aqueous NaOH. Ether extraction ( $2 \times 50$  mL), drying the ether layer over anhydrous  $\text{Na}_2\text{SO}_4$  and concentration *in vacuo* afforded 105 mg (81%) of 3-bromo-*o*-phenylenediamine (**3b**).  $^1\text{H}$  NMR 500 MHz (DMSO- $d_6$ ):  $\delta$  [ppm]: 10 (s, ext. br,  $\text{NH}_2 \times 2$ ), 7.43 (dd, 1H,  $J = 1.3$  Hz,  $J = 7.9$  Hz, H-5), 7.28 (dd, 1H,  $J = 1.3$  Hz,  $J = 7.9$  Hz, H-7), 6.62 (t, 1H,  $J = 7.9$  Hz, H-6):

(a) A solution of 80 mg (0.43 mmol) of 3-bromo-*o*-phenylenediamine (**3b**) in 1 mL of AcOH and 0.4 mL of  $\text{H}_2\text{O}$  was cooled to 0  $^\circ\text{C}$ , followed by addition of 48.9 mg (0.71 mmol) of sodium nitrite in 0.3 mL of water. The mixture was stirred for 1 h at room temperature, and the resulting precipitate collected by filtration and recrystallized from dilute ethanol to give 70 mg (83%) of pure product **3c**.

(b) A 0.5 g portion (1.9 mmol) of the dihydrochloride of 3-bromo-*o*-phenylenediamine (**3b**) was dissolved in 10 mL of water, 0.5 mL of conc. HCl, and 5 mL of EtOH. The solution was cooled to 0  $^\circ\text{C}$ , and 220 mg (3.1 mmol) sodium nitrite in 2 mL of water was added all at once. The mixture was stirred for 1 h at room temperature, and the resulting precipitate collected by filtration and recrystallized from dilute ethanol to give 240 mg (63%) of pure product **3c**: mp 183.5–185.5  $^\circ\text{C}$ ;  $R_f$  (A) 0.63, (B) 0.69; UV  $\lambda_{\text{max}}$  ( $\epsilon$ ): (pH 2) 267.5 nm (8465); (pH 7) 272 nm (8660); (pH 12) 280 nm (10350);  $^1\text{H}$  NMR  $\delta$ : 16.13 (br s, 1H-NH), 7.89 (br s, 1H, H-5), 7.67 (d, 1H,  $J = 6.6$  Hz, H-7), 7.4 (t, 1H,  $J = 7.7$  Hz, H-6);  $^{13}\text{C}$  NMR  $\delta$ : 140.79, 138.03, 128.30, 128.45, 113.88, 109.13; MS for  $\text{C}_6\text{H}_5\text{BrN}_3$  [ $\text{M}+\text{H}$ ] $^+$ : found, 197.96629; calcd, 197.96668.

**4,7-Dibromo-2,1,3-benzothiadiazole (4a).** A 5 g portion (37 mmol) of 2,1,3-benzothiadiazole (**2**) was suspended in 15 mL of 47% HBr. The mixture was heated under reflux with stirring, and 5.65 mL (110 mmol) of  $\text{Br}_2$  was added dropwise very slowly ( $\sim 3$  h). The mixture was then heated for another 2 h and the residue collected by filtration. Recrystallization from AcOH with addition of EtOH, and then from EtOH, gave 7.02 g (65%) of pure product **4a**: mp 188.4–189.5  $^\circ\text{C}$  [lit. 188–189  $^\circ\text{C}$ <sup>37</sup>];  $R_f$  (C) 0.85;  $^1\text{H}$  NMR:  $\delta$  [ppm]: 7.73 (s, 2H, H-5, H-6).

**4,7-Dibromobenzotriazole (4c, 4,7-Br<sub>2</sub>Bt).** A 2 g portion (6.83 mmol) of 4,7-dibromo-2,1,3-benzothiadiazole (**4a**) was dissolved in 108 mL of THF and 40 mL of EtOH. The mixture was cooled to 0  $^\circ\text{C}$ , and 4.4 g (116 mmol) cooled  $\text{NaBH}_4$  was added portionwise. The mixture was then stirred for 20 h. Following removal of solvent,  $\text{H}_2\text{O}$  was added and the mixture extracted with diethyl ether. The organic phase was washed with brine and dried over  $\text{Na}_2\text{SO}_4$ . Evaporation *in vacuo* gave 80% yield of the diamine **4b**:  $^1\text{H}$  NMR 500 MHz (DMSO- $d_6$ ):  $\delta$  [ppm]: 6.64 (s, 2H), 5.00 (s, 4H,  $\text{NH}_2$ ), which was then used to obtain 4,7-dibromobenzotriazole (**4c**) by the same procedure as for 4-bromobenzotriazole (**3c**, see above), in 75% yield: mp 255.5–257.1 (dec.);  $R_f$  (A) 0.6, (B) 0.82; UV  $\lambda_{\text{max}}$  ( $\epsilon$ ): (pH 2) 275 nm (9140), 292 nm (8260); (pH 7) 286 nm (11810); (pH 12) 285 nm (12621);  $^1\text{H}$  NMR  $\delta$ : 16.64 (br s, NH), 7.63 (s, 2H, H-5, H-6);  $^{13}\text{C}$  NMR  $\delta$ : 139.80, 129.93, 107.26; MS for  $\text{C}_6\text{H}_4\text{Br}_2\text{N}_3$  [ $\text{M}+\text{H}$ ] $^+$ : found, 277.87412; calcd, 277.87515.



**5-Bromo-2,1,3-benzothiadiazole (5a).** To a suspension of 8 g (0.03 mol) of 4-Br-1,2-phenylenediamine (**5b**) dihydrochloride in dry toluene (70 mL) was added 10 mL (0.14 mol) of thionyl chloride. The mixture was heated under reflux for 1 h, followed by addition of 5 mL of thionyl chloride and 2 mL of dry pyridine. Heating was continued for an additional 19 h. All fractions boiling to 150 °C were collected. Steam distillation of the residue, and recrystallization of the product from EtOH/water, afforded 5-bromo-2,1,3-benzothiadiazole (**5a**) in 70% yield: mp 59.1–60.3 °C [lit. 59–61 °C<sup>37</sup>];  $R_f$  (C) 0.85;  $^1\text{H}$  NMR:  $\delta$  [ppm]: 8.23 (dd, 1H,  $J$  = 0.61 Hz, 1.83 Hz, H-4); 7.88 (dd, 1H,  $J$  = 0.61 Hz, 9.28 Hz, H-7); 7.68 (dd 1H  $J$  = 1.83 Hz, 9.28 Hz, H-6).

**4,5-Dibromo-2,1,3-benzothiadiazole (6a).** To a solution of 500 mg (2.65 mmol) of 5-bromo-2,1,3-benzothiadiazole (**5a**) in 4 mL of boiling HBr was added 140  $\mu\text{L}$  (2.7 mmol) of  $\text{Br}_2$  in three portions within 3 h, and heating continued for 18 h. The reaction mixture was poured into ice water, filtered, washed with hot water, and dried. Purification by silica gel column chromatography with chloroform (stab./amylene) and recrystallization from MeOH gave 579 mg (66%) of pure 4,5-dibromo-2,1,3-benzothiadiazole (**6a**): mp 133.3–134.7 °C [lit. 134–136 °C<sup>37</sup>];  $^1\text{H}$  NMR  $\delta$ : 7.84, 7.8 (as. d, 2H,  $J$  = 9.19 Hz, H-5, H-6).

**4,5-Dibromobenzotriazole (6c, 4,5- $\text{Br}_2\text{Bt}$ ).** To a cooled (–5 °C) suspension of 150 mg (0.51 mmol) of 4,5-dibromo-2,1,3-benzothiadiazole (**6a**) in 10 mL of EtOH was added, portionwise, 334 mg (8.82 mmol) of  $\text{NaBH}_4$  at –5 °C and the mixture stirred for 21 h at room temperature. Following evaporation *in vacuo*,  $\text{H}_2\text{O}$  was added and the mixture extracted with diethyl ether. The organic layer was washed with water and dried over anhydrous sodium sulfate. Evaporation of solvent gave 107 mg (79%) of the crude diamine **6b**, which was used to obtain 4,5-dibromobenzotriazole (**6c**) by the same procedure as for 4-bromobenzotriazole (**3c**, see above), in 70% yield: mp 265 °C (dec);  $R_f$  (A) 0.64, (B) 0.71; UV  $\lambda_{\text{max}}$  ( $\epsilon$ ): (pH 2) 273 nm (8370); (pH 7) 285 nm (9865); (pH 12) 285 nm (11000);  $^1\text{H}$  NMR  $\delta$ : 16.22 (s, NH), 7.87 (d, 1H,  $J$  = 8.7 Hz, H-6), 7.74 (d, 1H,  $J$  = 8.7 Hz, H-7);  $^{13}\text{C}$  NMR  $\delta$ : 142.04, 137.49, 131.26, 121.44, 115.52, 111.3; MS for  $\text{C}_6\text{H}_4\text{Br}_2\text{N}_3$  [ $\text{M}+\text{H}$ ] $^+$ : found, 277.87407; calcd, 277.87515.

**4,6-Dibromobenzotriazole (7c, 4,6- $\text{Br}_2\text{Bt}$ ).** To a stirred solution of 1.5 g (5 mmol) of 2,4-dibromo-6-nitroaniline (**7**) in a mixture of 15 mL of ethyl acetate and 7 mL of EtOH was added, at ambient temperature, 4.86 g (25 mmol) of  $\text{SnCl}_2$ . The mixture was refluxed for 2 h, the solvent removed *in vacuo*, the residue basified with 2N NaOH, and extracted with diethyl ether. The extract was washed with brine, dried over  $\text{Na}_2\text{SO}_4$ , and evaporated. The residue was dissolved in n-hexane/EtOH (2:1), and conc. HCl/isopropanol (1:5) was added. The resulting precipitate was filtered off, and washed with n-hexane to give 1 g (59%) of the crude dihydrochloride of 3,5-dibromo-*o*-phenylenediamine (**7b**), which was then used to obtain 4,6-dibromobenzotriazole (**7c**) by the same procedure as for 4-bromobenzotriazole, in 79% yield: mp 276.2–278.7 °C [lit. 288–290 °C<sup>43</sup>];  $R_f$  (A) 0.66, (B) 0.77; UV  $\lambda_{\text{max}}$  ( $\epsilon$ ): (pH 2) 275 nm (8500); (pH 7) 284 nm (8950); (pH 12) 285 nm (9645);  $^1\text{H}$  NMR  $\delta$ : 16.32 (br s, NH), 8.2 (s, 1H, H-7), 7.87 (s, 1H, H-4);  $^{13}\text{C}$  NMR  $\delta$ : 140.74, 138.73, 130.7, 119.85, 116.67, 110.92; MS for  $\text{C}_6\text{H}_4\text{Br}_2\text{N}_3$  [ $\text{M}+\text{H}$ ] $^+$ : found, 277.87409; calcd, 277.87515.


**5,6-Dibromobenzotriazole (8c, 5,6- $\text{Br}_2\text{Bt}$ ).** This compound was obtained as for 4-bromobenzotriazole, from 4,5-dibromo-*o*-phenylenediamine (**8b**) according to a previous procedure,<sup>44</sup>

mp 261 °C (dec);  $R_f$  (A) 0.64, (B) 0.75; UV  $\lambda_{\text{max}}$  ( $\epsilon$ ): (pH 2) 296 nm (5700), 276 nm (5340); (pH 7) 294 nm (7630); (pH 12) 293 nm (9340);  $^1\text{H}$  NMR  $\delta$ : 8.44 (s, 2H, H-4, H-7);  $^{13}\text{C}$  NMR  $\delta$ : 139.2, 120.74, 119.84. MS for  $\text{C}_6\text{H}_4\text{Br}_2\text{N}_3$  [ $\text{M}+\text{H}$ ] $^+$ : found, 277.87406; calcd, 277.87515.


**1,2,3-Tribromo-5,6-dinitrobenzene (9a).** A mixture of 0.5 g (1.4 mmol) of 1,2,3-tribromo-5-nitrobenzene (**9**) in 2 mL of fuming nitric acid and 0.5 mL of conc. sulphuric acid was heated at 100 °C for 5 h. After cooling, the product was poured into a large quantity of cold water. The resulting precipitate was collected by filtration and washed with water. The yield of **9a** was quantitative; mp 161–162.3 °C [lit. 160 °C<sup>45</sup>];  $^1\text{H}$  NMR 500 MHz (DMSO)  $\delta$ : 8.8 (s, 1H, H-6);  $^{13}\text{C}$  NMR 500 MHz (DMSO)  $\delta$ : 143.15, 138.64, 137.43, 129.4, 128.5, 120.01.

**4,5,6-Tribromobenzotriazole (9c, 4,5,6- $\text{Br}_3\text{Bt}$ ).** 300 mg (0.741 mmol) of 1,2,3-tribromo-4,5-dinitrobenzene (**9a**) was ground in a mortar with 1.4 g (7.41 mmol) of  $\text{SnCl}_2$  and added gradually, within 1.5 h, to 10 mL of conc. HCl at 80 °C. The resulting precipitate was collected and basified with 2N NaOH to give 225 mg (82%) of pure 3,4,5-tribromo-1,2-diaminobenzene (**9b**):  $^1\text{H}$  NMR 500 MHz (DMSO- $d_6$ )  $\delta$ : 6.88 (s, 1H), 5.26 (s, 2H-NH<sub>2</sub>), 5.1 (s, 2H-NH<sub>2</sub>). This was used to obtain


Scheme 2



Scheme 3



Scheme 4



4,5,6-tribromobenzotriazole (**9c**) as for 4-bromobenzotriazole, in 83% yield; mp 301–304 °C; UV  $\lambda_{\text{max}}$  ( $\epsilon$ ): (pH 7) 286 nm (11810); (pH 12) 285 nm (12620);  $^1\text{H}$  NMR  $\delta$ : 8.45 (s, 1H, H-7), 16.44 (br s, NH);  $^{13}\text{C}$  NMR  $\delta$ : 141.57, 137.86, 124.15, 122.47, 118.76, 113.19. MS for  $\text{C}_6\text{H}_4\text{Br}_2\text{N}_3$   $[\text{M}+\text{H}]^+$ : found, 355.78447; calcd, 355.78566.

**QM Methods.** *Ab initio* calculations were performed for the neutral derivatives in their three possible protonation states, N(1)–H, N(2)–H, and N(3)–H (Scheme 2), and for the monoanionic forms with the aid of Firefly (PC GAMESS) version 7.1.<sup>46</sup> Initial coordinates of TBBt were adopted from its

crystal structure in a complex with maize CK2 $\alpha$ ,<sup>47</sup> while the structures of other halogenated Bt derivatives were built by subsequent replacement of bromine atoms in TBBt by hydrogens. All structures were preoptimized, using the semiempirical PM3 method, and then analyzed using the DFT B3LYP/6-31G(d,p) method, previously found adequate for modeling of benzotriazole derivatives.<sup>30,32</sup> Corrections for solute–solvent interactions were estimated using the polarizable continuum model (PCM).<sup>48</sup> Zero-point energies, and thermal corrections for translational, rotational, and vibrational degrees of freedom, were used to convert internal energies to Gibbs free energies at 298.15 K. ESP charges, calculated for optimized molecules, were then used in molecular mechanics calculations to parametrize electrostatic interactions.

Differences in free energy were analyzed for (a) dissociation of the triazole N–H proton ( $\Delta G_{\text{diss}}$ ), (b) solvation ( $\Delta G_{\text{solv}}$ ), and (c) protomeric equilibria for the neutral forms shown in Scheme 2 ( $\Delta G_1$ ,  $\Delta G_2$ ,  $\Delta G_3$ ), according to the following formulas:

$$\Delta G_{\text{diss}} = G_{\text{solv}}(\text{monoanion}) - G_{\text{solv}}(\text{neutral}) + G_{\text{hydr}}(\text{H}^+)$$

$$\Delta G_{\text{solv}} = G_{\text{solv}} - G_0$$

$$G_{\text{solv}} = E_{\text{elec}} + G_{\text{rep}} + G_{\text{disp}} + E_{\text{cav}} + E_{\text{zp}} + G_{\text{trans}} + G_{\text{rot}} + G_{\text{vib}}$$


$$\Delta G_i = G_{\text{solv}}(\text{state } i) - \min_{j=1,2,3} (G_{\text{solv}}(\text{state } j))$$

where  $G_0$  is the QM-derived Gibbs free energy *in vacuo* and the free energy of proton hydration,  $G_{\text{hydr}}(\text{H}^+)$ , was taken as  $-262.3$  kcal/mol.<sup>49</sup> Molecular volumes were calculated according to the algorithm of tessellation implemented in the GEPOL package.<sup>50</sup>


### 3. RESULTS AND DISCUSSION

**Synthetic Procedures.** 4-Bromobenzotriazole (**3c**) and 4,7-dibromobenzotriazole (**4c**) (Scheme 3) were obtained *via* direct bromination with  $\text{Br}_2$  of 2,1,3-benzothiadiazole (**2**) in 47% HBr.<sup>37</sup> The molar ratio of bromine to **2** was 1:1 for 4-bromobenzothiadiazole and 3:1 for the 4,7-dibromo analogue.

Scheme 5



Scheme 6



Scheme 7




Table 1. Experimental Values for Triazole Proton Dissociation ( $\text{pK}_a$ ) of Bromo-Benzotriazoles and Aqueous Solubility ( $C_w$ )<sup>a</sup>

compound	$M_w$	$n_{4,7}$	$n_{5,6}$	$\text{p}K_a$	$C_w$ (M)	$V_{\text{mol}}$ ( $\text{\AA}^3$ )		$\Delta G_{\text{solv}}$ (kcal/mol)		$\Delta G_1$ (kcal/mol)	$\Delta G_2$ (kcal/mol)	$\Delta G_3$ (kcal/mol)	
						neutral	anion	$\Delta G_{\text{diss}}$ (kcal/mol)	neutral				anion
Bt	119.1	0	0	8.56	$1.96 \times 10^{-1}$	130.3	127.1	59.5	−3.1	−59.9	0.00	5.40	0.03
4-BrBt (3c)	198.0	1	0	7.08	$3.87 \times 10^{-3}$	154.1	151.1	56.7	−1.0	−53.3	0.45	5.75	0.00
5-BrBt (5c)	198.0	0	1	7.55	$2.77 \times 10^{-3}$	154.0	151.3	58.1	−1.8	−50.7	0.65	5.87	0.00
4,5-Br <sub>2</sub> Bt (6c)	276.9	1	1	6.49	$4.99 \times 10^{-4}$	175.2	172.1	54.3	−1.9	−46.8	0.70	4.99	0.00
4,6-Br <sub>2</sub> Bt (7c)	276.9	1	1	6.38	$2.34 \times 10^{-4}$	178.0	174.7	54.2	−0.6	−45.5	0.09	5.82	0.00
4,7-Br <sub>2</sub> Bt (4c)	276.9	2	0	5.84	$1.98 \times 10^{-3}$	177.9	174.9	53.4	2.1	−48.0	0.00	4.06	0.06
5,6-Br <sub>2</sub> Bt (8c)	276.9	0	2	6.93	$2.31 \times 10^{-4}$	175.2	172.4	55.8	−0.4	−44.4	0.06	4.85	0.00
4,5,6-Br <sub>3</sub> Bt (9c)	355.8	1	2	5.91	$6.23 \times 10^{-5}$	195.6	192.8	52.3	0.0	−40.9	0.00	4.00	0.01
4,5,7-Br <sub>3</sub> Bt	355.8	2	1	5.38	$1.04 \times 10^{-3}$	198.7	195.9	52.2	3.7	−41.9	0.00	5.51	0.05
TBBt	434.7	2	2	4.78	$2.18 \times 10^{-4}$	216.1	213.0	49.7	5.3	−38.0	0.00	5.58	0.03

<sup>a</sup>Included also are the molar mass and number of Br atoms (0, 1, or 2) attached to the peripheral ( $n_{4,7}$ ) and central ( $n_{5,6}$ ) carbons of the benzene ring, molecular volumes ( $V_{\text{mol}}$ ) of neutral and anionic forms of brominated Bt derivatives, *ab initio* derived free energies of proton dissociation ( $\Delta G_{\text{diss}}$ ), free energies of solvation of both forms ( $\Delta G_{\text{solv}}(\text{neutral})$ ,  $\Delta G_{\text{solv}}(\text{anion})$ ), and relative free energies of the three possible protomers of the neutral forms ( $\Delta G_1$ ,  $\Delta G_2$ ,  $\Delta G_3$ ).

The sulfur extrusion reaction was performed by two different methods, depending on the number of bromine atoms. Reduction of 4-bromobenzothiadiazole (3a) to 3-bromo-*o*-phenylenediamine (3b) made use of  $\text{SnCl}_2/\text{HCl}$ ,<sup>51</sup> whereas 4,7-dibromobenzothiadiazole (4a) was reduced with  $\text{NaBH}_4$  in THF/ethanol. It should be noted that ring-opening of 4,7-dibromobenzothiadiazole (4a) in EtOH at 0 °C<sup>52</sup> virtually did not proceed, even with long reaction times, but the presence of THF gave the product in 80% yield. Ring closure of 3b and 4b with  $\text{NaNO}_2$  in HCl or AcOH led to 4-bromobenzotriazole (3c) and 4,7-dibromobenzotriazole (4c), respectively, in relatively good yields.

The starting compound for synthesis of 3,4-dibromobenzotriazole (6c) was 4-Br-1,2-phenylenediamine (5b), which was synthesized according to previously reported procedures for bromination of 2-nitroaniline with *N*-bromosuccinimide (NBS) to 4-bromo-2-nitroaniline,<sup>38</sup> followed by reduction with  $\text{SnCl}_2$  in ethanol. Ring closure of the dihydrochloride 5b with thionyl chloride in the presence of pyridine gave 5-bromo-2,1,3-benzothiadiazole (5a) in 70% yield. On the other hand, ring closure by nitrous-acid-promoted cyclization of 5b was previously shown to lead to 5-bromobenzotriazole (5c) (Scheme 4). Direct bromination of 5a gave 4,5-dibromobenzothiadiazole (6a) in 66% yield.

Sulfur extrusion, leading to 6b, was carried out as for 4c with  $\text{NaBH}_4$ , but without the presence of THF, in 79% yield. It should be recalled (see above) that rapid reduction of 3a was obtained by using  $\text{SnCl}_2$  as a reducing agent. However, reduction of dibromo analogues under these conditions can lead to removal of one atom of bromine. 3,4-Dibromo-*o*-phenylenediamine (6b), in nitrous-acid-promoted cyclization, gave 4,5-dibromobenzotriazole (6c) in 70% yield.

4,6-Dibromobenzotriazole (7c) (see Scheme 5) was obtained in 79% yield from 3,5-dibromo-*o*-phenylenediamine (7b), which was prepared by reduction of commercially available 2,4-dibromo-6-nitroaniline (7) with  $\text{SnCl}_2$  in EtOH.<sup>53</sup>

The preparation of 5,6-dibromobenzotriazole (8c, see Scheme 6) was based on an earlier report,<sup>39</sup> in which *o*-phenylenediamine (1) was tosylated to enable subsequent selective bromination, leading to formation of its 4,5-dibromo congener (8a). Removal of blocking groups gave 4,5-dibromo-*o*-phenylenediamine (8b), ring closure of which led to 5,6-dibromobenzotriazole (8c) in 86% yield.


The synthesis of 4,5,6-tribromobenzotriazole (9c) (Scheme 7), starting from 1,2,3-tribromo-5-nitrobenzene (9), involved nitration of the latter with  $\text{HNO}_3/\text{H}_2\text{SO}_4$  to yield, quantitatively, 1,2,3-tribromo-5,6-dinitrobenzene (9a), reduction of which with  $\text{SnCl}_2$  in HCl for 1.5 h gave the appropriate diamine (9b).

It was noted that treatment of 9a with iron powder<sup>54</sup> in HCl led to reduction of only one nitro group. Ring closure of 2,3,4-tribromo-*o*-phenylenediamine (9b) led to 4,5,6-tribromobenzotriazole (9c) in 83% yield.

**Physico-Chemical Properties.** The aqueous solubility at neutral pH of the brominated Bt derivatives decreases with the number of Br atoms attached to the benzene ring, the values being significantly modulated by the location of the Br atoms. Generally, C(4)/C(7)-substituted derivatives are much more soluble than their C(5)/C(6) counterparts, which carry the same number of Br atoms. In consequence, 4,7-Br<sub>2</sub>Bt and 4,5,7-Br<sub>3</sub>Bt dissolve at a higher concentration, while the solubilities of TBBt, 4,5,6-Br<sub>3</sub>Bt, and other dibromo derivatives are 10–100

times lower. Interestingly, the solubility of TBBt is almost 4-fold higher than that of less brominated 4,5,6-Br<sub>3</sub>Bt.

**Ionic Equilibria.** Experimental values of  $\text{pK}_a$  for dissociation of the triazole proton in aqueous medium demonstrate that each Br atom attached to the benzene ring increases the acidity of the compound (Table 1), but the final effect depends on the pattern of substitution. The results obtained with the aid of the SPARC server<sup>55</sup> clearly show that the effect of bromination on  $\text{pK}_a$  for dissociation of the triazole proton is underestimated (see Figure 1A). However, the regression statistic is acceptable



**Figure 1.** Correlation of experimental  $\text{pK}_a$  values of brominated benzotriazoles with (A) those predicted with the aid of the SPARC server (<http://archemcalc.com/sparc>), (B) values obtained from multilinear regression, based on the number of Br atoms (0, 1, or 2) located at C(4), C(7) and/or C(5), C(6), and (C) the *ab initio* calculated free energy of dissociation ( $\Delta G_{\text{diss}}$ ) of the triazole proton.

but with no visible changes in  $\text{pK}_a$  related to variation in location of bromine atoms. The latter stimulated us to perform a multidimensional regression analysis, which revealed that the effect of attachment of bromine atoms is almost additive, but there are two pairs of equivalent locations, C(4), C(7) and C(5), C(6) (Figure 1B). This indicates that each bromine atom attached at the peripheral C(4) or C(7) decreases  $\text{pK}_a$  by the same value 1.10 ( $\pm 0.04$ ), and those attached at the central

Table 2. Assignments of Resonance Lines in the  $^{13}\text{C}$  Spectra of Brominated Benzotriazoles Recorded in DMSO/ $\text{H}_2\text{O}$  (99:1)<sup>a</sup>

compound	$^{13}\text{C}$ chemical shifts (ppm) and (in brackets) resonance line widths (Hz)									
	C(4a)	C(7a)	C(4)	C(7)	C(5)	C(6)				
Bt		138.2 (1000)		115.1 (507)		125.8 (88)				
4-BrBt (3c)	140.8	(50) 138.0	(58)	109.1	(145) 113.8	(107)	128.5*	(25)	128.3*	(23)
5-BrBt (5c)	139.9*	(10) 137.9*	(10)	117.5*	(10) 117.0*	(10)	118.3	(3)	128.5	(3)
4,5-Br <sub>2</sub> Bt (6c)	142.0*	(44) 137.5*	(58)	111.3	(47) 115.5	(38)	121.4	(26)	131.3	(25)
4,6-Br <sub>2</sub> Bt (7c)	138.7*	(237) 140.7*	(265)	110.9	(155) 116.7	(143)	130.7	(43)	119.9	(62)
4,7-Br <sub>2</sub> Bt (4c)		139.8 (48)		107.3 (43)			129.9 (20)			
5,6-Br <sub>2</sub> Bt (8c)		139.2 (12)		119.8 (6)			120.7 (3)			
4,5,6-Br <sub>3</sub> Bt (9c)	141.6*	(62) 137.9*	(93)	113.2	(78) 118.8	(60)	124.2*	(35)	122.5*	(34)
4,5,7-Br <sub>3</sub> Bt	140.6*	(5) 139.6*	(5)	110.1*	(4) 108.8*	(4)	122.9	(3)	132.7	(3)
TBBt		139.0 (57)		111.0 (57)			124.7 (14)			

<sup>a</sup>Assignments within the potentially equivalent C4a/C7a, C4/C7, and C5/C6 resonance pairs (see Scheme 2), denoted by an asterisk, were based on GIAO-derived  $^{13}\text{C}$  magnetic shielding parameters (see Figure 2 in the Supporting Information for the general correlation between experimental and theoretical data).

C(5) or C(6) by  $0.57 (\pm 0.04)$ . It should be noted that the  $\text{pK}_a$  of the parent Bt deviates from the regression line. The expected value of 8.12 differs significantly from experimental values, reported as 8.56,<sup>32</sup> 8.67,<sup>56</sup> and 8.38.<sup>34</sup> This deviation from the additivity scheme indicates that solvation of the parent Bt differs quantitatively from its brominated derivatives.

The low aqueous solubility of the neutral form of TBBt also makes  $\text{pK}_a$  measurements difficult, since a high quality low-pH UV spectrum could not be recorded. In consequence, the  $\text{pK}_a$  values of  $4.87 \pm 0.22$ <sup>32</sup> and  $5.1 \pm 0.3$ <sup>30</sup> were estimated for the same sample, using as reference either the noisy UV spectrum recorded at pH 2 or the spectrum recorded in methanol. An earlier  $\text{pK}_a$  was estimated as close to 5.<sup>57</sup>

**$^{13}\text{C}$  NMR: Resonance Assignments and Protomeric Equilibria.** For most compounds, the  $^{13}\text{C}$  NMR spectra, recorded in anhydrous DMSO, display significant broadening of the resonance lines, with widths exceeding 50 Hz (see Figure 2 in the Supporting Information). By contrast, the resonance lines of 5-BrBt and 5,6-Br<sub>2</sub>Bt are narrow, with widths characteristic for low-mass solutes (C(4a), C(7a)  $\sim 10$  Hz, C(5), C(6)  $\sim 2.5$  Hz, C(4), C(7)  $\sim 10$  Hz), and (C(4a)/C(7a)  $\sim 10$  Hz, C(5)/C(6)  $\sim 3$  Hz, C(4)/C(7)  $\sim 10$  Hz) for 5-BrBt and 5,6-Br<sub>2</sub>Bt, respectively. The observed significant resonance line broadening clearly must be attributed to a dynamic prototropic equilibrium, since addition of a small amount of water results in significant narrowing of all resonance lines (Figure 2 in the Supporting Information, right panels). The most evident effect was previously reported for the parent Bt<sup>32</sup> and TBBt,<sup>30</sup> for which, in anhydrous medium, separate signals of the chemically equivalent C(4) and C(7) resonances were observed, due to virtual asymmetry caused by slow exchange between the N(1)-H and N(3)-H protomers (Scheme 2).

Assignments of individual  $^{13}\text{C}$  resonances were supported by quantum mechanical (GIAO) calculations of carbon nuclei shielding, using the HF/6-311G basis set, which was previously found adequate for the parent benzotriazole (1)<sup>58,59</sup> and a series of its symmetrically substituted derivatives.<sup>32</sup> For nonhalogenated carbons, the shielding, averaged according to the assumed 1:1 equilibrium between the N(1)-H and N(3)-H neutral forms, was found significantly correlated with the experimental chemical shift values ( $R^2 = 0.92$ , see Figure 1 in the Supporting Information). Consequently, these shielding values were used to help in assignment of ambiguous C(4a)/C(7a) and other resonances, denoted by asterisks in Table 2. The HF/6-311G basis set was found inadequate for prediction of the location of  $^{13}\text{C}$  resonances of halogenated carbons.

**QM Calculations.** For each molecule, the following thermodynamic properties were estimated: (a) free energy of proton dissociation,  $\Delta G_{\text{diss}}$ ; (b) free energy of solvation,  $\Delta G_{\text{solv}}$  (difference between free energy in solution and *in vacuo*); (c) protomeric equilibrium between the three possible protonation states of the neutral form (Scheme 2). The overall data are summarized in Table 1.

**Free Energy of Proton Dissociation.** Free energies of proton dissociation,  $\Delta G_{\text{diss}}$ , estimated independently with the aid of *ab initio* methods (Table 1), almost perfectly reconstruct the order of experimental  $\text{pK}_a$  data (Figure 1C). For TBBt, the  $\text{pK}_a$  value of 4.87 agrees with that predicted by multidimensional regression analysis (Figure 1B,  $\text{pK}_a$  4.78) and also with the calculated free energy of dissociation. Hence, the  $\text{pK}_a$  of  $4.87 \pm 0.22$  for TBBt is used in all further analyses.

**Free Energy of Solvation.** As expected, according to the LCW theory,<sup>60</sup> the values of  $\Delta G_{\text{solv}}$  determined for both neutral and dissociated molecules, are well correlated with the molecular volume,  $V_{\text{mol}}$ . The noticeable deviations (Figure 2)





Figure 2. *Ab initio* calculations of the free energy of solvation ( $\Delta G_{\text{solv}}$ ) of all possible brominated derivatives of benzotriazole, for their neutral (○) and ionic (●) forms, represented according to LCW theory as a function of solute molecular volume. The small, but noticeable, deviations between derivatives with the same number of Br atoms (and of similar volume) are ascribed to site-specific hydration, due to variations in accessibility of Br atoms to the aqueous solvent, and to differences in electron density distribution by the patterns of location of the Br atoms.

are directly related to structure-dependent specific hydration. Derivatives with the same number of Br atoms on the benzene ring differ both in molecular volume and free energy of



solvation. In general, derivatives with Br atoms at vicinal carbons, e.g., 4,5-Br<sub>2</sub>Bt, 5,6-Br<sub>2</sub>Bt, or 4,5,6-Br<sub>3</sub>Bt, differ in molecular volume from those with an alternative pattern of Br substitution, such as 4,6-Br<sub>2</sub>Bt, 4,7-Br<sub>2</sub>Bt, or 4,5,7-Br<sub>3</sub>Bt. Solvent-related changes in free energy for monoanionic forms are the reverse of those calculated for the neutral forms of the same compounds. This implies that, apart from purely electronic effects, interactions with the aqueous solvent also significantly affect the  $pK_a$  values for dissociation of the triazole proton.

**Aqueous Solubility.** Inspection of the  $pK_a$  dependence of solute solubility (see Figure 3A) enables clusterization of the



**Figure 3.** Prediction of solubility ( $C_{w,exp}$ ) of brominated benzotriazoles, based (A) on their  $pK_a$  values for dissociation of the triazole proton, (B) on their molecular volumes, and (C) on *ab initio* calculations. The  $pK_a$  dependence clearly distinguished between the effects of halogenation of the benzene ring at the central (C5, C6) and peripheral (C4, C7) carbon atoms, while the log-regression model ( $C_{w,calc}$ ), which corrects for the effect of uniform hydrophobic solvation (according to LCW theory, proportional to the molecular volume) for the free energies of dissociation and solvation, reasonably well predicts experimental solubility.

studied compounds into three well-separated groups differing by the number of bromine atoms attached to the peripheral locations of benzene ring (i.e., C4 and C7, see Scheme 2). Within each group, the logarithm of solubility is an almost linear function of experimentally determined values of  $pK_a$  for dissociation of the triazole proton. This clearly confirms that the ionic equilibrium is the significant factor influencing solubility of halogenated benzotriazoles, although other factors related to the topology of halogenation pattern must also be taken into account.

According to the LCW theory of solvation of hydrophobic molecules in aqueous medium, the free energy of solute–solvent interactions is proportional to the molecular volume of the solute molecule.<sup>60</sup> Thus, to a first approximation, neglecting differences in free energy of intermolecular interactions in the solid state, the logarithms of experimentally measured aqueous solubility are expected to be a linear function of solute volumes (see Figure 3B).

The observed marked deviation from an expected common exponential trend between the volume of a molecule and its aqueous solubility indicates that specific solute–solvent interactions cannot be neglected. In principle, the effect of a Br atom strongly depends on the substitution pattern; hence, the total effect should be regarded as location-specific, indicating that hydration significantly depends on the pattern of Br substitution, rather than on the number of Br atoms. The analyzed compounds cluster into two groups, Bt, and three derivatives with both peripheral carbons (C4, C7) brominated: 4,7-Br<sub>2</sub>Bt, 4,5,7-Br<sub>3</sub>Bt, TBBt, and 4-BrBt, 5-BrBt, 4,5-Br<sub>2</sub>Bt, 4,6-Br<sub>2</sub>Bt, 5,6-Br<sub>2</sub>Bt, 4,5,6-Br<sub>3</sub>Bt, within each of which the solubility is strictly correlated with molecular volume. The increased solubility of the three derivatives brominated at 4,7 is strictly related to their decreased  $pK_a$ , stabilizing the anionic forms in neutral aqueous solution.


The question arises as to how precisely the *ab initio* calculations may estimate the specific solute–solvent interactions. In fact, the three-parameter log-regression model, which correctly predicts the solubility of all compounds, with only a small deviation for 4-BrBt, is as follows:

$$\log(C_w) \propto (0.19 \pm 0.04) \cdot V_{mol} + \frac{G_{diss}}{RT} - \frac{G_{solv}(\text{anion})}{RT}$$

This relation indicates that the general trend of a decrease in solubility with an increase in volume of the solute molecule (indicating hydrophobic solvation) is significantly modulated by specific solute–solvent interactions determined for the monoanionic state of the molecule and, consequently, by its population. As anticipated, ligands that are preferentially solvated, and largely dissociated, display higher solubility (Figure 3C).

**Preliminary Biological Implications.** Inhibitory activities against CK2 $\alpha$  were tested using the P81 filter isotopic assay.<sup>61</sup> The reaction mixture contained 20 mM Tris–HCl, pH 7.5, 20 mM MgCl<sub>2</sub>, 20  $\mu$ M DTT, 20  $\mu$ M peptide substrate, 0.5 mM  $\beta$ -glycerol, 0.1 mM EGTA, 10  $\mu$ M ATP (200–300 cpm/pmol), CK2 $\alpha$  (0.4  $\mu$ g/ $\mu$ L), and 50  $\mu$ M tested compound. The estimated levels of reduction of enzymatic activity of CK2 $\alpha$  were found correlated with free ligand solubilities ( $R^2 = 0.69$ , see Figure 4A) and QM-derived free energies of solvation, corrected for QM-derived energies for proton dissociation (Figure 4B,  $R^2 = 0.85$ ). It is worth noting that the last correlation successfully predicts that inhibitory activity of compounds 8c and 9c is close to that of TBBt, notwithstanding





**Figure 4.** Correlation of experimentally determined inhibition of CK2 $\alpha$  by 50  $\mu$ M solutions of halogenated benzotriazoles with (A) their aqueous solubilities,  $C_{w,exp}$ , and (B) QM-derived free energies of solvation,  $\Delta G_{solv}$ , corrected for free energies of dissociation of the triazole proton,  $\Delta G_{diss}$ .

that they differ by the number of halogen atoms attached to the benzene ring. Moreover, these two simple thermodynamic parameters adequately distinguish activity of various isomers carrying the same number of bromine atoms, unequivocally confirming that hydrophobic and electrostatic interactions predominate in inhibitory activities of halogenated benzotriazoles.

#### 4. CONCLUSIONS

Physico-chemical properties in aqueous medium were analyzed for all nine possible isomers of benzotriazole brominated on the benzene ring. Both the number and location of halogen atoms were found to substantially modulate the  $pK_a$  for dissociation of the triazole proton.  $^{13}\text{C}$  NMR spectra recorded in anhydrous DMSO demonstrated existence of a protomeric equilibrium, which, according to QM calculations, occurs between the N(1)–H and the N(3)–H neutral forms. The number of halogen atoms, and their locations, were found to significantly modulate solubility in aqueous medium. Thus, the solvation of halogenated benzotriazoles must be driven by a subtle balance between electrostatic and hydrophobic interactions. The variation of solution properties resulting from different patterns of halogenation clearly show that, in drug design studies on halogenated ligands, solvation of their nonbound forms cannot be neglected. QM-derived free energies for solvation and proton dissociation were found to be reasonably good predictors of inhibitory activity.

#### ■ ASSOCIATED CONTENT

##### Supporting Information

Supplementary figures demonstrating (1) correlation between GIAO-derived  $^{13}\text{C}$  shielding and experimentally measured chemical shift and (2) a complete set of NMR  $^{13}\text{C}$  spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.

#### ■ AUTHOR INFORMATION

##### Corresponding Author

\*E-mail: shugar@ibb.waw.pl (D.S.); jarek@ibb.waw.pl (J.P.).

##### Present Address

<sup>§</sup>Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, Warsaw, Poland.

##### Notes

The authors declare no competing financial interest.

#### ■ REFERENCES

- (1) Wang, W.; Okada, Y.; Wang, Y.; Okuyama, T. *J. Nat. Prod.* **2005**, *68*, 620–622.
- (2) Pauletti, P. M.; Cintra, L. S.; Braguine, C. G.; da Silva Filho, A. A.; Silva, M. L.; Cunha, W. R.; Januário, A. H. *Mar. Drugs* **2010**, *8*, 1526–1549.
- (3) Hernandez, M. Z.; Cavalcanti, S. M. T.; Moreira, D. R. M.; Azevedo, W. F., Jr.; Leite, A. C. L. *Curr. Drug Targets* **2010**, *11*, 303–314.
- (4) Lu, Y.; Wang, Y.; Zhu, W. *Phys. Chem. Chem. Phys.* **2010**, *12*, 4543–4551.
- (5) <http://www.rcsb.org>.
- (6) Voth, A. R.; Ho, P. S. *Curr. Top. Med. Chem.* **2007**, *7*, 1336–1348.
- (7) Parisini, E.; Metrangolo, P.; Pilati, T.; Resnati, G.; Terraneo, G. *Chem. Soc. Rev.* **2011**, *40*, 2267–2278.
- (8) Metrangolo, P.; Meyer, F.; Pilati, T.; Resnati, G.; Terraneo, G. *Angew. Chem., Int. Ed.* **2008**, *47*, 6114–6127.
- (9) Metrangolo, P.; Resnati, G. *Science* **2008**, *321*, 918–919.
- (10) Chudzinski, M. G.; Taylor, M. S. *J. Org. Chem.* **2012**, *77*, 3483–3491.
- (11) Sarwar, M. G.; Dragisic, B.; Salsberg, L. J.; Gouliaras, C.; Taylor, M. S. *J. Am. Chem. Soc.* **2010**, *132*, 1646–1653.
- (12) Lu, Y.; Li, H.; Zhu, X.; Liu, H.; Zhu, W. *Int. J. Quantum Chem.* **2011**, *112*, 1421–1430.
- (13) Mugnaini, V.; Punta, C.; Liantonio, R.; Metrangolo, P.; Recupero, F.; Resnati, G.; Pedulli, G. F.; Lucarini, M. *Tetrahedron Lett.* **2006**, *47*, 3265–3269.
- (14) Glaser, R.; Chen, N.; Wu, H.; Knotts, N.; Kaupp, M. *J. Am. Chem. Soc.* **2004**, *126*, 4412–4419.
- (15) Hauchecorne, D.; van der Veken, B. J.; Moiana, A.; Herrebout, W. *Chem. Phys.* **2010**, *374*, 30–36.
- (16) Bertsev, V. V.; Golubev, N. S.; Shchepkin, D. N. *Opt. Spektrosk.* **1976**, *40*, 951–953.
- (17) Lu, Y.; Li, H.; Zhu, X.; Zhu, W.; Liu, H. *J. Phys. Chem. A* **2011**, *115*, 4467–4475.
- (18) Auffinger, P.; Hays, F. A.; Westhof, E.; Ho, P. S. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 16789–16794.
- (19) Voth, A. R.; Hays, F. A.; Ho, P. S. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, *104*, 6188–6193.
- (20) Carter, M.; Ho, P. S. *Cryst. Growth Des.* **2011**, *11*, 5087–5095.
- (21) Kraut, D. A.; Sigala, P. A.; Fenn, T. D.; Herschlag, D. *Proc. Natl. Acad. Sci. U.S.A.* **2010**, *107*, 1960–1965.
- (22) Hardegger, L. A.; Kuhn, B.; Spinnler, B.; Anselm, L.; Ecabert, R.; Stihle, M.; Gsell, B.; Thoma, R.; Diez, J.; Benz, J.; Plancher, J. M.; Hartmann, G.; Isshiki, Y.; Morikami, K.; Shimma, N.; Haap, W.; Banner, D. W.; Diederich, F. *ChemMedChem* **2011**, *6*, 2048–2054.
- (23) Eckenhoff, R. G.; Johansson, J. S. *Pharmacol. Rev.* **1997**, *49*, 343–361.

- (24) Liu, R.; Loll, P. J.; Eckenhoﬀ, R. G. *FASEB J.* **2005**, *19*, 567–576.
- (25) Pop, S. M.; Gupta, N.; Raza, A. S.; Ragsdale, S. W. *J. Biol. Chem.* **2006**, *281*, 26382–26390.
- (26) Memic, A.; Spaller, M. R. *ChemBioChem* **2008**, *9*, 2793–2795.
- (27) Szyszka, R.; Grankowski, N.; Felczak, K.; Shugar, D. *Biochem. Biophys. Res. Commun.* **1995**, *208*, 418–424.
- (28) Zieñ, P.; Bretner, M.; Zastapilo, K.; Szyszka, R.; Shugar, D. *Biochem. Biophys. Res. Commun.* **2003**, *306*, 129–133.
- (29) Sarno, S.; Papinutto, E.; Franchin, C.; Bain, J.; Elliott, M.; Meggio, F.; Kazimierczuk, Z.; Orzesko, A.; Zanotti, G.; Battistutta, R.; Pinna, L. A. *Curr. Top. Med. Chem.* **2011**, *11*, 1340–1351.
- (30) Wąsik, R.; Łebska, M.; Felczak, K.; Poznański, J.; Shugar, D. *J. Phys. Chem. B* **2010**, *114*, 10601–10611.
- (31) De Moliner, E.; Brown, N. R.; Johnson, L. N. *Eur. J. Biochem.* **2003**, *270*, 1–8.
- (32) Poznański, J.; Najda, A.; Bretner, M.; Shugar, D. *J. Phys. Chem. A* **2007**, *111*, 6501–6509.
- (33) Borowski, P.; Deinert, J.; Schalinski, S.; Bretner, M.; Ginalski, K.; Kulikowski, T.; Shugar, D. *Eur. J. Biochem.* **2003**, *270*, 1645–1653.
- (34) Hansen, L. D.; West, B. D.; Baca, E. J.; Blank, C. L. *J. Am. Chem. Soc.* **1978**, *90*, 6588–6592.
- (35) Hwang, J. S.; Schilf, R.; Drach, J. C.; Townsend, L. B.; Bogner, E. *Antimicrob. Agents Chemother.* **2009**, *53*, 5095–5101.
- (36) Wiley, R. H.; Hussung, K. F. *J. Am. Chem. Soc.* **1957**, *79*, 4395–4400.
- (37) Pilgram, K.; Zupan, M.; Skiles, R. J. *Heterocycl. Chem.* **1970**, *7*, 629–633.
- (38) Gershon, H.; Clarke, D. D.; Gershon, M. *Monatsh. Chem.* **1994**, *125*, 723–730.
- (39) Cheeseman, G. W. H. *J. Chem. Soc.* **1962**, 1171–1176.
- (40) Cobas, C.; Cruces, J.; Sardina, F. J. MestRe-C 2.3a, Magnetic Resonance Companion NMR Data Processing Program. Departamento de Química Orgánica, Facultad de Química, Universidad de Santiago de Compostela, 1706 Santiago de Compostela Spain.
- (41) Marquardt, D. W. *J. Soc. Ind. Appl. Math.* **1963**, *11*, 431–441.
- (42) Williams, T.; Kelley, C. Gnuplot 2004 Version 4.0, <http://www.ucc.ie/gnuplot>.
- (43) Ratnikov, M. O.; Lipilin, D. L.; Churakov, A.; Strelenko, M.; Yu, A.; Tartakovsky, V. A. *Org. Lett.* **2002**, *4*, 3227–3229.
- (44) Vagin, S.; Frickenschmidt, A.; Kammerer, B.; Hanack, M. *Eur. J. Org. Chem.* **2005**, *15*, 3271–3278.
- (45) Jackson, C. L.; Fiske, A. H. *Am. Chem. J.* **1916**, *53*, 148–154.
- (46) Schmidt, M. W.; Baldridge, K. K.; Boatz, J. A.; Elbert, S. T.; Gordon, M. S.; Jensen, J. J.; Koseki, S.; Matsunaga, N.; Nguyen, K. A.; Su, S.; Windus, T. L.; Dupuis, M.; Montgomery, J. A. *J. Comput. Chem.* **1993**, *14*, 1347–1363.
- (47) Battistutta, R.; De Moliner, E.; Sarno, S.; Zanotti, G.; Pinna, L. A. *Protein Sci.* **2001**, *10*, 2200–2206.
- (48) Tomasi, J.; Cammi, R.; Mennucci, B. *Int. J. Quantum Chem.* **1999**, *75*, 767–783.
- (49) Tawa, G. J.; Topol, I. A.; Burt, S. K.; Caldwell, R. A.; Rashin, A. A. *J. Chem. Phys.* **1998**, *109*, 4852–4863.
- (50) Pascual-Ahuir, J. L.; Silla, E.; Tomasi, J.; Bonaccorsi, R. *J. Comput. Chem.* **1987**, *8*, 778–787.
- (51) Tsubata, Y.; Suzuki, T.; Miyashi, T.; Miyashita, Y. *J. Org. Chem.* **1992**, *57*, 6749–6755.
- (52) Edelmann, M. J.; Raimundo, J. M.; Utesch, N. F.; Diederich, F. *Helv. Chim. Acta* **2002**, *85*, 2195–2213.
- (53) Rangarajan, M.; Kim, J. S.; Sim, S. P.; Liu, A.; Liu, L. F.; La Voie, E. J. *Bioorg. Med. Chem.* **2000**, *8*, 2591–2600.
- (54) Youngblood, W. J. *J. Org. Chem.* **2006**, *71*, 3345–3356.
- (55) Hilal, S.; Karickhoff, S. W.; Carreira, L. A. *Quant. Struct.-Act. Relat.* **1995**, *14*, 348–355.
- (56) Wiley, R. H.; Hussung, K. H.; Moffat, J. *J. Am. Chem. Soc.* **1955**, *77*, 5105–5108.
- (57) Zien, P.; Duncan, J. S.; Skierski, J.; Bretner, M.; Litchfield, D. W.; Shugar, D. *Biochim. Biophys. Acta* **2005**, *1754*, 271–280.
- (58) Schilf, W.; Stefaniak, L.; Witanowski, M.; Webb, G. A. *Magn. Reson. Chem.* **1985**, *23*, 181–184.
- (59) Wiench, J. W.; Stefaniak, L.; Barszczewicz, A.; Webb, G. A. *J. Mol. Struct.* **1994**, *327*, 321–326.
- (60) Lum, K.; Chandler, D.; Weeks, J. D. *J. Phys. Chem. B* **1999**, *103*, 4570–4577.
- (61) Olsen, B.; Rasmussen, T.; Niefind, K.; Issinger, O. G. *Mol. Cell. Biochem.* **2008**, *316*, 37–47.